Evidence map›Paper›PMID 38982161›Full record

ArticleScientific reports2024

Employing antagonistic C-X-C motif chemokine receptor 4 antagonistic peptide functionalized NaGdF

Xiaodong Li, Yunkai Bao, Zhuheng Li, Peihong Teng, Lina Ma, Hua Zhang, Guifeng Liu, Zhenxin Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaodong LiDepartment of Radiology, China-Japan Union Hospital of Jilin University, 130033, Changchun, People's Republic of China.
Yunkai BaoState Key Laboratory of Electroanalytical Chemistry, Chinese Academy of Sciences, Changchun Institute of Applied Chemistry, 130022, Changchun, People's Republic of China.
Zhuheng LiJilin Provincial Institute of Education, 130024, Changchun, People's Republic of China. lizhuheng@126.com.
Peihong TengDepartment of Radiology, China-Japan Union Hospital of Jilin University, 130033, Changchun, People's Republic of China.
Lina MaSchool of Traditional Chinese Medicine, Jilin Agriculture Science and Technology College, 132101, Jilin, People's Republic of China.
Hua ZhangState Key Laboratory of Electroanalytical Chemistry, Chinese Academy of Sciences, Changchun Institute of Applied Chemistry, 130022, Changchun, People's Republic of China.
Guifeng LiuDepartment of Radiology, China-Japan Union Hospital of Jilin University, 130033, Changchun, People's Republic of China. gfliu@jlu.edu.cn.
Zhenxin WangState Key Laboratory of Electroanalytical Chemistry, Chinese Academy of Sciences, Changchun Institute of Applied Chemistry, 130022, Changchun, People's Republic of China. wangzx@ciac.ac.cn.ORCID 0000-0002-1908-9848

Funding

Jilin Provincial Education Department JJKH20230463KJScience and Technology Developing Foundation of Jilin Province 20220101078JC
6 · The paper itself

Abstract

C-X-C motif chemokine receptor 4 (CXCR4) is a promising therapeutic target of breast cancer because it is overexpressed on cell surface of all molecular subtypes of breast cancer including triplenegative breast cancer (TNBC). Herein, CXCR4 antagonistic peptide-NaGdF

Indexed as

Breast NeoplasmsMagnetic Resonance ImagingReceptors, CXCR4AnimalsCell Line, TumorChemokine CXCL12FemaleGadoliniumHumansMiceMice, Inbred BALB CMice, NudeNanoparticlesPeptidesPeptides, CyclicXenograft Model Antitumor AssaysChemokine CXCL12CXCR4 protein, humanGadoliniumPeptidesPeptides, CyclicReceptors, CXCR4BiotherapyC-X-C motif chemokine receptor 4 antagonistic peptideNaGdF4 nanodot conjugatesT1-weighted magnetic resonance imaging

Identifiers

PMID38982161
PMCPMC11233619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.